Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,044 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor.
Fukushima S, Endo M, Matsumoto Y, Fukushi JI, Matsunobu T, Kawaguchi KI, Setsu N, IIda K, Yokoyama N, Nakagawa M, Yahiro K, Oda Y, Iwamoto Y, Nakashima Y. Fukushima S, et al. Among authors: nakagawa m. PLoS One. 2017 May 30;12(5):e0178064. doi: 10.1371/journal.pone.0178064. eCollection 2017. PLoS One. 2017. PMID: 28558056 Free PMC article.
Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
Nakagawa M, Fujita S, Katsumoto T, Yamagata K, Ogawara Y, Hattori A, Kagiyama Y, Honma D, Araki K, Inoue T, Kato A, Inaki K, Wada C, Ono Y, Yamamoto M, Miura O, Nakashima Y, Kitabayashi I. Nakagawa M, et al. Cancer Sci. 2019 Jan;110(1):194-208. doi: 10.1111/cas.13840. Epub 2018 Nov 16. Cancer Sci. 2019. PMID: 30343511 Free PMC article.
Diagnosis and Management of Subcutaneous Soft Tissue Sarcoma.
Endo M, Setsu N, Fujiwara T, Ishii T, Nakagawa M, Yahiro K, Kimura A, Shimada E, Nakashima Y, Matsumoto Y. Endo M, et al. Among authors: nakagawa m. Curr Treat Options Oncol. 2019 May 25;20(7):54. doi: 10.1007/s11864-019-0656-z. Curr Treat Options Oncol. 2019. PMID: 31129726 Review.
Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Nakagawa M, Nakatani F, Matsunaga H, Seki T, Endo M, Ogawara Y, Machida Y, Katsumoto T, Yamagata K, Hattori A, Fujita S, Aikawa Y, Ishikawa T, Soga T, Kawai A, Chuman H, Yokoyama N, Fukushima S, Yahiro K, Kimura A, Shimada E, Hirose T, Fujiwara T, Setsu N, Matsumoto Y, Iwamoto Y, Nakashima Y, Kitabayashi I. Nakagawa M, et al. Oncogene. 2019 Oct;38(42):6835-6849. doi: 10.1038/s41388-019-0929-9. Epub 2019 Aug 12. Oncogene. 2019. PMID: 31406254
A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
Machida Y, Nakagawa M, Matsunaga H, Yamaguchi M, Ogawara Y, Shima Y, Yamagata K, Katsumoto T, Hattori A, Itoh M, Seki T, Nishiya Y, Nakamura K, Suzuki K, Imaoka T, Baba D, Suzuki M, Sampetrean O, Saya H, Ichimura K, Kitabayashi I. Machida Y, et al. Among authors: nakagawa m. Mol Cancer Ther. 2020 Feb;19(2):375-383. doi: 10.1158/1535-7163.MCT-18-1349. Epub 2019 Nov 14. Mol Cancer Ther. 2020. PMID: 31727689
4,044 results